Welcome to our dedicated page for Inspira Technologies Oxy Bhn SEC filings (Ticker: IINN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-trial timelines, FDA submissions and patent claims make Inspira Technologies Oxy BHN Ltd.’s disclosures some of the most technical on EDGAR. Finding when the INSPIRA ART system hits a regulatory milestone or spotting HYLA sensor revenue projections inside a 10-K can feel like hunting for a pulse in 300 pages. If you have ever typed “Inspira Technologies SEC filings explained simply” into a search bar, you already know the challenge.
Stock Titan solves it. Our AI parses every annual report 10-K, quarterly earnings report 10-Q filing and 8-K material event the moment it lands, then highlights what matters—cash runway, clinical data, supply-chain agreements and risk factors—so you can focus on decisions, not document mining. Activate real-time alerts for Inspira Technologies Form 4 insider transactions real-time and track sentiment through “Inspira Technologies insider trading Form 4 transactions” or “Inspira Technologies executive stock transactions Form 4.”
- Compare R&D spend quarter-over-quarter with “Inspira Technologies earnings report filing analysis.”
- Review pay packages via “Inspira Technologies proxy statement executive compensation.”
- Stay ahead of surprises with “Inspira Technologies 8-K material events explained.”
Whether you’re understanding Inspira Technologies SEC documents with AI or confirming distribution-agreement details, our platform offers AI-powered summaries, plain-English explanations and complete access to every filing type. No more guessing where HYLA fits into segment reporting or how insiders are trading ahead of trial results—Stock Titan keeps you informed, confident and ready.
Inspira Technologies Oxy B.H.N. Ltd. (IINN) furnished a Form 6-K announcing a press release titled “Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission.”
The Company states that the first three and fifth paragraphs and the “Forward-Looking Statements” section of the press release are incorporated by reference into its Registration Statements on Form F-3 (Nos. 333-266748, 333-284308, 333-289324) and Form S-8 (Nos. 333-259057, 333-277980, 333-285565, 333-290162).
Inspira Technologies Oxy B.H.N. Ltd. (IINN) furnished a Form 6-K announcing a press release titled “Inspira Technologies Nears Final Regulatory Clearance for the ART100 in the UAE, Accelerating Gulf Region Expansion.” The press release is attached as Exhibit 99.1.
The filing states that the first, second, and fourth paragraphs, along with the “Forward-Looking Statements” section of the press release, are incorporated by reference into the company’s Registration Statements on Form F-3 and Form S-8, to be a part thereof from the date of this report, to the extent not superseded.
Inspira Technologies (IINN) furnished a Form 6-K announcing a press release titled “Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira’s Global Ecosystem.” The filing notes that the first four paragraphs and the “Forward-Looking Statements” section of the release are incorporated by reference into the company’s existing registration statements on Form F-3 and Form S-8, effective upon submission.
Inspira Technologies Oxy B.H.N. Ltd. (IINN) filed a Form 6-K announcing leadership additions. On October 21, 2025, the company furnished a press release titled “Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm.”
The first three paragraphs and the “Forward-Looking Statements” section of the release are incorporated by reference into Inspira’s Registration Statements on Forms F-3 and S-8, effective from the submission date, to the extent not superseded by later filings.
Inspira Technologies Oxy B.H.N. Ltd. submitted a Form 6-K that incorporates by reference previously filed registration statements and furnishes a press release dated September 18, 2025. The press release announces that Inspira will unveil its HYLA™ real-time blood sensor at the U.S. ELSO conference and states the device has 97.35% accuracy confirmed. The filing is signed by Chief Executive Officer Dagi Ben-Noon. The document provides an event announcement and a specific accuracy figure for the product but does not include financial results, commercialization details, regulatory approvals, or timelines.
FAQ
What is the current stock price of Inspira Technologies Oxy Bhn (IINN)?
What is the market cap of Inspira Technologies Oxy Bhn (IINN)?
